IDEXX's stock has surged, boasting strong 12-month returns. However, how does it truly measure up against key animal health peers rapidly advancing in a growing veterinary diagnostics market? As of November 25, 2025, IDXX exhibits robust LTM revenue growth and impressive operating and free cash flow margins. Yet, its premium P/E ratio of 59.77 suggests a demanding valuation compared to some rivals, indicating potentially limited upside despite solid fundamentals and positive analyst sentiment.
IDXX's 31.3% operating margin is robust, but ZTS's 37.6% reflects superior scale efficiencies and broader diversification.IDXX's 8.4% LTM revenue growth outpaces some peers, indicating strong diagnostic utilization, but PAHC may target faster-growing niches.IDXX's 78.9% stock gain and 59.8 PE reflect high growth expectations, yet PAHC's stronger returns hint at even greater investor appeal.
Here's how IDEXX Laboratories stacks up across size, valuation, and profitability versus key peers.
IDXXMRKZTSELANPAHCMarket Cap ($ Bil)61.4263.656.611.61.8Revenue ($ Bil)4.264.29.44.61.4PE Ratio59.813.921.4323.326.4LTM Revenue Growth8.4%1.7%2.7%3.1%33.7%LTM Operating Margin31.3%34.9%37.6%5.2%10.3%LTM FCF Margin22.6%20.3%23.8%7.7%2.4%12M Market Return78.9%8.3%-27.5%75.0%86.5%
For more details on IDEXX Laboratories, read Buy or Sell IDXX Stock. Below we compare IDXX's growth, margin, and valuation with peers across years
